期刊文献+

基于中医理论的恶性肿瘤生活质量评价体系之共性量表的研制:测量学特性评价 被引量:9

Development of the General Module of Quality of Life Assessment System for Cancer Based on Traditional Chinese Medicine:Psychometric Properties
下载PDF
导出
摘要 目的分析评价基于中医理论的恶性肿瘤生活质量评价体系之共性量表(QLASTCM-GM)的测量学特性(信度、效度与反应度)。方法通过240例肺癌和240例胃癌患者纵向的生命质量测定对QLASTCM-GM的测量学特性进行评价。结果各领域及总量表的重测信度均在0.93以上,内部一致性α值为0.86~0.93;相关分析与因子分析显示量表有较好的结构效度;与癌症患者生活质量测定量表(QLQ-C30)的相关分析显示具有较好的效标关联效度;治疗后各领域及总量表得分间差异均有统计学意义(P<0.05),且标准化反应均数(SRM)较QLQ-C30大。结论 QLASTCM-GM具有较好的信度、效度及一定的反应度,可用于癌症患者生命质量的测定。 Objective To evaluate psychometric properties (reliability, validity, and responsiveness) of the general module of the quality of life assessment system for cancer based on Traditional Chinese Medicine ( QLASTCM - GM) . Methods QLASTCM - GM was evaluated by quality of life (QOL) data measured from a longitudinal study of 240 patients of lung cancer and 240 patients of gastric cancer. Results The test - retest reliabilities for all domains and the overall scale were above O. 93, thectvalue of internal consistency for all domains were fromO. 86 to 0. 93. Correlation analysis and factor analysis displayed a good construct validity; Criterion -related validity was confirmed by correlation analysis with cancer's 30 -item quality of life questionnaire ( QLQ - C30) ; Statistically significant changes ( P 〈0. 05 ) after treatment were found for each domain ( P 〈0. 05 ) and the overall scale, and the standardized response mean (SRM) was greater than that of QLQ - C30. Conclusion The QLASTCM - GM can be used to measure QOL for patients of cancer with good validity and reliability, and. reasonable responsiveness.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第4期390-393,共4页 Chinese General Practice
基金 国家重点基础研究发展计划("973"计划2006CB504604) 广东省高等学校人才引进专项资金项目(GK1003)
关键词 肿瘤 生命质量 信度 效度 反应度 Neoplasms Quality of life Reliability Validity Responsiveness
  • 相关文献

参考文献5

二级参考文献13

  • 1万崇华,孟琼,罗家洪,汤学良,张灿珍,卢玉波,杨铮,张晓磬.癌症患者生命质量测定量表体系共性模块的研制(一):条目筛选及共性模块的形成[J].癌症,2007,26(2):113-117. 被引量:67
  • 2Johnson JR,Temple R.Food and drug administration requirements for approval of new anticancer drugs[J].Cancer Treat Rep,1985,69:1155-1157.
  • 3Anronson NK,Meyerowits BE,Bard M,et al.Quality of life research in oncology:Past achievements and future priorities[J].Cancer,1991,67:839-843.
  • 4Aaronson NK,Cull A,Kaasa S,et al.The EORTC modular approach to quality of life assessment in oncology[J].Int J Ment Health,1994,23:75-96.
  • 5Cella DF,Tulsky DS,Gray G,et al.The functional assessment of cancer therapy scale:Development and validation of the general measure[J].Journal of Clinical Oncology,1993,11(3):570-579.
  • 6Wan CH,Yang Z,Meng Q,et al.Development and Validation of the General Module of the System of Quality of Life Instruments for Cancer Patients(QLICP-GM)[J].International Journal of Cancer,2008,122(1):190-196.
  • 7The WHOQOL Group.The Word Health Organization Quality of Life assessment (WHOQOL):Devolvement and psychometric properties[J].Soc Sci Med,1998,46(12):1569-1585.
  • 8Aaronson NK,Ahmedzai S,Bergman B,et al.The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology[J].J Natl Cancer Inst,1993,85:365-376.
  • 9Brucker PS,Yost K,Cashy J,et al.General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General(FACT-G)[J].Evaluation & the Health Professions,2005,28(2):192-211.
  • 10Johnson JR,Temple R. Food and drug administration requirements for approval of new anti-cancer drugs[J]. Cancer Treat Rep, 1985,69(10) : 1155-1157.

共引文献1318

同被引文献98

引证文献9

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部